Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Sun Pharma Advanced Research Company Ltd (SPARC) is currently trading at 212.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage biopharmaceutical company focusing on drug creation and novel delivery systems. Their work spans new chemical entities and novel drug delivery systems (NDDS) for global markets. SPARC engages in strategic licensing agreements, enabling Sun Pharma to commercialize drugs like Xelpros and Elepsia XR in the US market, showcasing the collaborative link between the two companies. The company has faced multiple regulatory hurdles, particularly with facilities flagged by USFDA for non-compliance, impacting drug approvals and delaying royalty income. SPARC's strategy includes global partnerships, granting exclusive rights for its assets to companies such as Visiox Pharma and China Medical Systems Ltd. to tap into international markets. Recent financial restructuring through equity conversion has altered SPARC's ownership structure, reducing the stake of its former holding company.
Over the past 52 weeks, Sun Pharma Advanced Research Company Ltd has traded between a low of ₹108.20 and a high of ₹289.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sun Pharma Advanced Research Company Ltd has a market capitalization of approximately 6,973.97. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sun Pharma Advanced Research Company Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 4.49 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 6,973.97 Cr, Sun Pharma Advanced Research Company Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sun Pharma Advanced Research Company Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sun Pharma Advanced Research Company Ltd is 4.49. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The stock surged after a US district court granted summary judgment in SPARC’s favour in the dispute over a Priority Review Voucher linked to Sezaby.
Sun Pharma reported a consolidated net profit of ₹3,117.95 crore for the quarter ended September 2025, representing a 2.6% increase year-on-year.
Shareholding Pattern
Sun Pharma Advanced Research Company Ltd received requests on 2026-07-27 from Mr. Sudhir V. Valia, Mrs. Raksha S. Valia and Mrs. Krishna V. Valia to reclassify from Promoter Group to Public; total 5,979,182 shares (1.85%).
Regulatory/Compliance Filing
Sun Pharma Advanced Research Company Ltd received on 2026-07-27 requests from certain promoter-group shareholders to reclassify as Public (total 5,979,182 shares; 1.85%). Requests to be examined and placed before the Board.
Bearish
3
Neutral
2
Bullish
9
Bearish
24
Neutral
2
Bullish
20
Bearish
21
Neutral
0
Bullish
11
Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage biopharmaceutical company focusing on drug creation and novel delivery systems. Their work spans new chemical entities and novel drug delivery systems (NDDS) for global markets.
SPARC engages in strategic licensing agreements, enabling Sun Pharma to commercialize drugs like Xelpros and Elepsia XR in the US market, showcasing the collaborative link between the two companies.
The company has faced multiple regulatory hurdles, particularly with facilities flagged by USFDA for non-compliance, impacting drug approvals and delaying royalty income.
SPARC's strategy includes global partnerships, granting exclusive rights for its assets to companies such as Visiox Pharma and China Medical Systems Ltd. to tap into international markets.
Recent financial restructuring through equity conversion has altered SPARC's ownership structure, reducing the stake of its former holding company.
Pharmaceuticals & Biotechnology
Pharmaceuticals
6,904 Cr
High Risk
4.4
37.2
0.1
5.2
289.00
108.20
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
3370.70 | 8,112 Cr | 19.63 | 9.43 | 3.49 | 42.11 | 52.41 | 25.64 | ||
569.15 | 7,075 Cr | 31.89 | 15.15 | 0.79 | 47.50 | 52.11 | 32.88 | ||
215.00 | 6,974 Cr | 4.49 | 5.21 | 0.00 | 116.01 | 80.89 | 71.55 | ||
845.50 | 6,799 Cr | 32.51 | 5.68 | 0.12 | 17.46 | 23.00 | 15.41 | ||
417.80 | 6,794 Cr | 24.14 | 2.73 | 1.20 | 11.32 | 15.18 | 9.64 | ||
1411.50 | 6,500 Cr | 56.34 | 6.96 | 0.00 | 12.36 | 14.43 | 7.58 | ||
685.65 | 6,217 Cr | 33.34 | 2.93 | 0.51 | 8.22 | 9.59 | 5.36 | ||
| Median: 7 Co. | — | 685.65 | 6,799 Cr | 31.89 | 5.68 | 0.51 | 17.46 | 23.00 | 15.41 |
